Jiangsu Hengrui Medicine: The Story of China's Pharma Goliath

I. Introduction & Episode Roadmap (~15 min)

On the morning of May 12, 2026, traders in Shanghai watched a stock that had spent five years under heavy market pressure hit its daily 10% upward limit. The trigger was an announcement from Princeton, New Jersey: Bristol Myers Squibb had agreed to pay 江苏恒瑞医药股份有限公司 Jiangsu Hengrui Pharmaceuticals $600 million in upfront cash, with near-term payments reaching $950 million and a total headline valuation of roughly $15.2 billion, for rights to a package of thirteen early-stage drug programs across oncology, hematology, and immunology.¹ Hengrui's Hong Kong-listed shares rose as much as 13% to HK$76.75, while its Shanghai shares closed up 4.8% after touching the limit intraday.²

What made the transaction notable was not merely its scale, but its direction of travel.

For most of the modern pharmaceutical era, drug development flowed from West to East: a Western multinational discovered a therapy, and a Chinese firm licensed it, manufactured it, or produced a generic version once the patent expired. In this transaction, one of the world's largest oncology franchises paid a manufacturer based in 连云港 Lianyungang — a port city on the Yellow Sea better known for container shipping and seafood than medicinal chemistry — for the right to develop its candidate molecules everywhere except Greater China.¹

In the same deal, Hengrui secured exclusive rights to commercialize four of BMS's immunology assets inside its own territory.¹ This two-way cross-licensing structure marks a distinct shift from historical cross-border pharmaceutical partnerships.

The company, in numbers

Hengrui trades as 600276.SS on the 上海证券交易所 Shanghai Stock Exchange and, since May 2025, as 1276.HK on the 香港交易所 Hong Kong Exchanges and Clearing.³ For 2025, the company reported revenue of RMB 31.63 billion — roughly $4.4 billion — a 13% increase year over year, with net profit attributable to shareholders of RMB 7.71 billion, up 21.7%.⁴ Its market capitalization stood at roughly RMB 319 billion in late May 2026, having fallen more than 70% from a peak above RMB 600 billion reached in the first weeks of 2021.⁵⁶ That valuation drawdown forms the central pivot of Hengrui's trajectory. Few large-cap pharmaceutical firms have lost two-thirds of their market value not because a core drug failed, a key patent expired, or accounting irregularities occurred, but because their primary customer — the Chinese government — fundamentally altered how it procures medicine.

This narrative follows an unusual trajectory. It begins in 1970 inside a state-owned factory producing bulk chemical ingredients, moves through a pivotal shift in capital allocation, builds a dominant domestic oncology business, sees that business systematically repriced by state policy, and ultimately pivots into a novel industry role: an early-stage research arbitrageur that discovers candidate molecules rapidly and cost-effectively in China before licensing them to Western partners equipped to fund late-stage clinical trials.

The roadmap

The company's transformation unfolds across six distinct phases: how a coastal chemical works evolved into a modern research organization with laboratories in Shanghai and global hubs; the 2014–2019 expansion when Hengrui established dominance in Chinese oncology; and the subsequent policy shock from 国家集中带量采购 volume-based procurement and the 国家医保药品目录 National Reimbursement Drug List, which compressed profit margins across both legacy generics and novel drugs.

The narrative then details the return of founder 孙飘扬 Sun Piaoyang following a 20-month retirement; the subsequent surge in global out-licensing deals — spanning Merck KGaA in 2023, GSK in 2025, and Bristol Myers Squibb in 2026 — and the central question facing investors: whether monetizing early-stage assets through foreign partners represents a durable business model or a temporary strategic transition.

That underlying tension frames the analysis that follows. Bullish investors argue Hengrui has established a structural edge: discovering candidate molecules and running early clinical trials faster and far more cheaply than Western peers, then realizing value before incurring the multi-hundred-million-dollar expenses of global Phase 3 development. Skeptics counter that these dynamics describe an outsourced R&D vendor for global pharmaceutical majors — collecting upfront cash and single-digit to low-double-digit royalties while long-term commercial upside accrues to partners like Bristol Myers Squibb and GSK — while Hengrui's domestic franchise remains vulnerable to a monopsony state buyer determined to lower drug prices. Both perspectives align with data available as of August 2026. Determining which thesis proves correct will depend on late-stage clinical readouts expected primarily in 2028 and beyond.

Evaluating these contrasting outlooks requires examining the company's origins in a modest provincial chemical plant.

↑ Back to Top

II. Lianyungang Roots & Sun Piaoyang's Early Bet (1970s–2000) (~25 min)

In 1990, Lianyungang was designated one of China's original fourteen coastal open cities for foreign investment, yet its local industrial base remained modest. The 连云港制药厂 Lianyungang Pharmaceutical Factory, founded in 1970, produced bulk active pharmaceutical ingredients — the industrial chemical inputs that other companies processed into finished medications. As a state-owned enterprise, the factory operated under fixed state production plans, yielding essentially nominal profits according to Chinese business press retrospectives.⁷

That year, a 32-year-old technician named Sun Piaoyang took over as factory director. Sun had joined the plant in 1982 after graduating from 中国药科大学 China Pharmaceutical University, spending eight years in a system where technical competence offered minimal financial reward.⁷

Colleagues and profile accounts consistently characterized Sun as an engineer rather than a merchant — a manager focused on chemical structures and synthesis routes who grew impatient with the narrow economics of contract ingredient manufacturing. That impatience triggered the factory's first strategic pivot.

Escaping the commodity

Bulk active pharmaceutical ingredients remain a commodity business driven by cost competition and thin margins set by the lowest-cost producers. By contrast, finished drug formulations — the dosage forms administered in hospitals — command brand equity, physician relationships, and pricing power uncoupled from raw chemical costs.

In 1991, Sun directed the factory into the anti-cancer injectable VP-16, or etoposide, and developed an improved oral capsule version that generated strong sales.⁷ The product demonstrated that the provincial plant could advance up the pharmaceutical value chain.

Later that year, Sun executed a far riskier transaction. He allocated roughly RMB 1.2 million — nearly the factory's entire annual profit — to acquire the patent rights for the anti-cancer drug ifosfamide from the 中国医学科学院药物研究所 Institute of Materia Medica, Chinese Academy of Medical Sciences.⁷ The capital commitment carried substantial risk: a state-owned plant in a secondary port city committed its full annual earnings to a single oncology molecule at a time when China's domestic oncology market was undeveloped and branded pharmaceuticals were rare. Without access to venture capital or public equity markets, a failure would have threatened the enterprise's survival.

The drug succeeded. Between 1991 and 1996, the factory launched over twenty new products, including five designated national key products, driving annual revenue past RMB 100 million by 1996.⁷

Beyond top-line growth, the initial product launches established Hengrui's long-term capital allocation pattern. Sun consistently reinvested cash flows from commercialized generic molecules into developing subsequent therapies, building an R&D focus long before competitors treated research as a core priority. The corporate strategy of reinvesting a substantial share of earnings — which eventually evolved into Hengrui's practice of allocating roughly a quarter of revenue to research — took root during this period.

Listing, and the geography of talent

Commercial expansion prompted structural reorganization. In 1997, the Lianyungang state enterprise was restructured into Hengrui Pharmaceutical, and in 2000, the company completed an initial public offering on the Shanghai Stock Exchange, securing access to capital markets.⁷

The capital raised funded two distinct initiatives: modern manufacturing facilities built to Good Manufacturing Practice standards, and a dedicated research center established in Shanghai rather than Lianyungang. Separating coastal manufacturing and corporate headquarters from urban research laboratories allowed the company to recruit top-tier scientific talent in Shanghai while maintaining low-cost production on the coast.

The buyout, and what it means for governance

The company's subsequent ownership transformation reshaped its long-term governance. Between 2003 and 2006, through China's nationwide share-structure reform and a management buyout, Sun succeeded the state as the controlling owner of the listed company.⁷

The controlling entity is 江苏恒瑞医药集团有限公司 Jiangsu Hengrui Pharmaceutical Group, controlled by Sun and his family, holding between 20% and 25% of the listed company depending on the vehicle and measurement date.⁸ While era-specific management buyouts of state assets drew scrutiny regarding valuation fairness, the transaction placed operational and equity control under a single owner-operator with a long-term investment horizon.

By 2000, Hengrui's operational foundation was established: a profitable finished-formulation business, a public listing, founder control with extended planning horizons, and an early commitment to internal drug discovery. The subsequent decades tested whether that domestic foundation could scale into novel drug development.

↑ Back to Top

III. The Innovative Transformation: Dominating Domestic Oncology (2001–2019) (~35 min)

Every pharmaceutical company graduating from generics to innovation reaches a point where research and development shifts from an operating expense to a core capital asset. For Hengrui, that transition unfolded over roughly fifteen years and remained largely invisible on its financial statements for much of that period.

Throughout the 2000s, the company pursued a deliberately disciplined strategy. Hengrui concentrated on small-molecule synthetic chemistry — its existing core competency — while targeting four therapeutic areas where Chinese hospital demand was elevated, prescriber concentration was dense, and the underlying science was tractable: oncology, contrast media for medical imaging, surgical anesthesia, and cardiovascular medicine.

Three of those segments operated through what the industry terms "hospital-channel" distribution. Products were sold directly to several thousand Class III hospitals through a specialized sales force, creating a commercial moat built on field headcount and hospital relationships rather than broad consumer brand marketing. Hengrui expanded its sales presence aggressively, building one of the largest pharmaceutical sales organizations in China — an investment that drove growth for a decade before later presenting structural cost challenges.

Apatinib, and a myth worth correcting

The company's first major regulatory milestone arrived in December 2014, when Chinese regulators approved apatinib mesylate, marketed as 艾坦 Aitan, for advanced gastric cancer.⁹ Apatinib is a small-molecule inhibitor of VEGFR-2, a vascular endothelial growth factor receptor that tumors utilize to establish blood supply; inhibiting the receptor starves the tumor of vasculature.

Gastric cancer represented a disproportionate disease burden in China, third-line treatment options were severely limited, and Hengrui brought a domestically approved, locally manufactured targeted therapy to market at a competitive price point.

The launch also exposed a common misconception in the company's corporate narrative. Hengrui often framed apatinib as China's first self-developed novel small-molecule anti-cancer drug. However, the compound — designated YN968D1 and later given the international nonproprietary name rivoceranib — was discovered by Advenchen Laboratories in Southern California and exclusively licensed to Hengrui for the China market in 2005, with rest-of-world rights allocated separately in 2007.⁹ Hengrui conducted a decade of clinical development in China, ran the registrational trials, secured regulatory approval, and established the commercial market. While representing substantial clinical execution, the molecule's origin was in-licensed rather than discovered in Lianyungang. For investors, the distinction highlights the specific capability Hengrui validated in 2014: advanced clinical development and domestic commercialization, rather than proprietary early-stage discovery.

"722": the day the competition disappeared

The second major structural shift was regulatory. On July 22, 2015, the China Food and Drug Administration issued an administrative directive known in the industry as "722," ordering sponsors of 1,622 pending drug registration applications to self-inspect their clinical trial data for authenticity.¹⁰

Applicants holding fabricated or incomplete clinical data were permitted to withdraw filings voluntarily by late August, while firms caught submitting fraudulent data faced a three-year ban on new drug applications.¹¹ Approximately 80% of all pending drug applications were subsequently withdrawn.¹¹

The directive fundamentally reshaped the competitive landscape of the Chinese pharmaceutical sector. In a single regulatory action, authorities eliminated the financial viability of low-quality generic filing mills and advantaged companies that had established rigorous clinical trial infrastructure. Hengrui, having invested in compliant clinical development capabilities while competitors relied on routine documentation filings, saw its regulatory backlog clear rapidly.

That enforcement action served as an essential catalyst for Hengrui's commercial expansion from 2015 through 2019. The company benefited not only from internal execution, but also from a regulatory environment that abruptly enforced the operational standards Hengrui had already adopted. This regulatory dependency carried dual implications: a commercial position reinforced by policy choices remains exposed when state policy shifts.

PD-1: the best commercial setup in China, briefly

The third strategic inflection occurred in biologics. In 2019, Hengrui launched 卡瑞利珠单抗 camrelizumab, a PD-1 checkpoint inhibitor monoclonal antibody designed to block the pathway tumors use to suppress T-cell immune responses. PD-1 inhibitors represented the largest oncology drug class globally, and Chinese regulators deliberately encouraged domestic development. Camrelizumab entered the market alongside three competing domestic therapies: 信达生物 Innovent Biologics' sintilimab, 君实生物 Junshi Biosciences' toripalimab, and 百济神州 BeiGene's tislelizumab. Backed by a large addressable patient population and a sales force reaching Class III hospitals nationwide, Hengrui occupied what initially appeared to be one of the most advantageous commercial positions in Chinese pharmaceuticals.

The power couple, and a governance footnote

Alongside product commercialization, the company's governance reflected a distinct family structure. Sun Piaoyang's wife, 钟慧娟 Zhong Huijuan, resigned from her position as a chemistry teacher in Lianyungang to found 翰森制药 Hansoh Pharmaceutical in 1995, building it into a major pharmaceutical manufacturer before listing it on the Hong Kong Stock Exchange. By late 2025, Forbes valued her net worth at approximately $19.7 billion, recognizing her as the world's wealthiest self-made woman.¹²

The existence of two independently listed pharmaceutical companies originating from the same city and controlled by spouses created a notable corporate structure. While Chinese business media frequently noted their joint industry prominence, governance analysts monitored the potential for related-party overlap between two public companies operating in adjacent therapeutic categories under shared family ownership. Although public disclosures revealed no improper intercompany transactions, the ownership structure remained an ongoing consideration for institutional investors.

By year-end 2019, Hengrui reported annual revenue of RMB 23.3 billion and net profit of RMB 5.33 billion, supported by RMB 3.9 billion in R&D expenditure. The company maintained high-teens earnings growth, a dominant domestic oncology franchise, and a premium market valuation reflecting its position as China's leading pharmaceutical major.

That market consensus assumed Hengrui's domestic commercial model would persist unchanged. However, that assumption was soon challenged by changes implemented by its primary institutional buyer.

↑ Back to Top

IV. The VBP & NRDL Shock: The Dark Days of 2020–2022 (~30 min)

Every analysis of the Chinese pharmaceutical sector eventually collides with a single structural reality: China is fundamentally a single-buyer market. Established in 2018, the 国家医疗保障局 National Healthcare Security Administration (NHSA) consolidated purchasing, reimbursement, and pricing authority for the national medical insurance system under one agency. Operating with a fixed budget and serving an aging population, the agency exercised its monopsony leverage to systematically compress drug costs.

How volume-based procurement actually works

To lower prices on off-patent drugs, the state deployed 国家集中带量采购 volume-based procurement (VBP). The mechanics were straightforward yet devastating for incumbents. The state aggregated demand for specific molecules across public hospitals nationwide and conducted centralized tenders. Winning bidders received guaranteed hospital volume—capturing a massive share of the national market without requiring a traditional sales force—while losing bidders were effectively shut out. Consequently, pharmaceutical firms stopped competing on physician relationships or sales detailing and competed strictly on price. Because the guaranteed volume was so valuable, bidding rapidly descended toward marginal production costs, driving price cuts between 70% and 90%.

For Hengrui, whose earnings remained heavily reliant on mature hospital injectables and contrast imaging agents, VBP eroded its core earnings base. Since 2018, 35 of the company's products were included in national procurement schemes, with 22 selected in bulk procurement rounds where prices dropped by an average of 74.5%.¹³

The impact was immediate. Eight Hengrui drugs included in the fifth national VBP round generated just RMB 250 million in revenue during the first half of 2022—an 88% year-over-year decline.¹³ Products that had funded two decades of corporate R&D were reduced to minor line items within a few tender cycles.

The PD-1 price war

While VBP targeted generic formulations, the state managed novel therapies through annual updates to the 国家医保药品目录 National Reimbursement Drug List (NRDL). Because public insurance covers the vast majority of Chinese hospital expenditures, exclusion from the NRDL leaves a drug commercially marginal. Inclusion requires negotiating directly with the NHSA on price.

The 2020 NRDL negotiations marked a turning point for oncology pricing, particularly for PD-1 checkpoint inhibitors. Domestic manufacturers accepted price reductions of roughly 80% to secure inclusion; Hengrui agreed to an 85% price cut for 卡瑞利珠单抗 camrelizumab, pricing it at RMB 2,928 per 200mg vial in exchange for reimbursed access across four approved indications.¹⁴ As a result, the annual per-patient cost for PD-1 therapy in China fell from the tens of thousands of dollars standard in Western markets to just a few thousand dollars.

An aggressive domestic rivalry compounded the margin compression. Four Chinese PD-1 developers competed directly against one another for reimbursement slots, while Western competitors—Merck's Keytruda, Bristol Myers Squibb's Opdivo, AstraZeneca's Imfinzi, and Roche's Tecentriq—failed to reach pricing agreements with the NHSA and were excluded from coverage.¹⁵ The domestic producers captured the market but stripped away its profitability. The episode illustrated the rapid commoditization of novel therapies in China: even clinically valuable molecules lost pricing power when multiple competent competitors launched within eighteen months into a single-buyer market.

The numbers, and what management did not say

Hengrui's financial results reflected the policy shifts with minimal lag. Annual revenue fell from RMB 27.7 billion in 2020 to RMB 25.9 billion in 2021, dropping further to RMB 21.3 billion in 2022—a cumulative 23% contraction over two years for a business long viewed as a consistent compounder. Net profit attributable to shareholders declined from RMB 6.33 billion in 2020 to RMB 4.53 billion in 2021, reaching RMB 3.91 billion in 2022.

Quarterly figures revealed even sharper stress. By the fourth quarter of 2021, revenue had dropped 31.4% year over year, while quarterly net profit plummeted 84.4%.¹³ First-half 2021 profit growth had already decelerated to its lowest rate in eighteen years, triggering a broad market sell-off.[^16] From a peak above RMB 600 billion in early 2021, Hengrui's market capitalization eventually declined by more than 70%.⁵

Corporate communications during the downturn drew criticism from institutional investors. Given the public nature of procurement calendars and transparent tender rules, the severe margin compression across mature generics was largely predictable. Nevertheless, management disclosures throughout 2021 provided limited quantitative detail on product-level exposure.

Compounding these operational headwinds was high-level executive turnover. Within roughly twelve months, four vice general managers left the firm, including the chief medical officer overseeing oncology development.¹³ The departures depleted senior leadership depth precisely as the company confronted its severe commercial contraction.

The founder comes back

In July and August 2021, founder Sun Piaoyang returned to executive leadership. Sun had relinquished day-to-day management in early 2020 to a professional successor as part of an intended generational transition. Twenty months later, with the company's valuation down significantly and its domestic commercial model under pressure, he resumed operational control.⁷

Sun immediately restructured the organization. He downsized the legacy sales force, reducing the generic-facing detailing teams that VBP had rendered economically obsolete, since winning centralized tenders eliminated the need for expansive hospital-level promotion. He then reoriented commercial teams around newly approved, innovative therapies.

Crucially, Sun redirected the corporate R&D budget away from fast-follower chemical compounds tailored for domestic commercialization, refocusing research on targets with global market potential.

That strategic shift redefined Hengrui's core thesis: if domestic reimbursement policy capped returns on internal R&D, the company had to monetize its early-stage research by licensing candidate molecules to international partners capable of commanding higher global prices. This pivot converted a domestic pricing constraint into an international business development strategy—an area where Hengrui had yet to demonstrate a proven track record.

↑ Back to Top

V. The Global BD & "NewCo" Revolution (2023–2026) (~40 min)

Underneath Hengrui's corporate slogan — the "dual-engine strategy" (双轮驱动 dual-engine strategy) combining domestic innovation with global out-licensing — lies a specific form of research-and-development cost arbitrage. To understand its financial mechanics requires examining how expenditures are distributed across the drug development lifecycle.

A new medicine's cost curve is heavily back-loaded. Early discovery and preclinical testing typically require tens of millions of dollars, while Phase 1 and Phase 2 clinical trials to establish safety, dosage, and initial efficacy signals cost an additional $50 million to $100 million. By contrast, global Phase 3 clinical trials — involving thousands of patients across multiple countries to satisfy regulatory authorities in the United States and Europe — routinely cost several hundred million dollars per indication, representing the phase where the vast majority of clinical failures and capital losses occur.

China's structural advantage in pharmaceutical research centers primarily on those initial stages. Abundant, cost-competitive chemistry talent, rapid patient recruitment driven by high hospital patient volumes, and streamlined regulatory pathways for early-stage trials significantly lower initial development costs.

Hengrui's value proposition to Western pharmaceutical majors leverages this cost differential: identifying validated biological targets, developing differentiated molecules, advancing them through clinical proof-of-concept in China at lower expense, and out-licensing late-stage global development rights in exchange for upfront cash, milestone payments, and royalties, while retaining commercial rights in Greater China.

For Western partners, this structure provides access to de-risked assets earlier and at lower initial cost than internal development. For Hengrui, it generates non-dilutive capital while pricing its discovery pipeline in competitive international markets rather than under domestic monopsony constraints.

Proof point one: Merck KGaA

The strategy's initial validation arrived on October 30, 2023, when Merck KGaA licensed HRS-1167 — a next-generation selective PARP1 trapping inhibitor — for worldwide development outside Greater China. Merck KGaA paid €160 million up front, with total potential transaction value reaching up to €1.4 billion, alongside an option on Hengrui's Claudin-18.2 antibody-drug conjugate SHR-A1904.¹⁶ Clinical selectivity for PARP1 offers potential advantages over first-generation PARP inhibitors, which target multiple PARP family members and frequently induce bone-marrow toxicity that restricts combination therapies. The asset represented an effort to refine a validated mechanism — an area where Chinese synthetic chemistry capabilities had demonstrated speed and efficiency.

Inventing the NewCo

In May 2024, Hengrui introduced a structural variation to its out-licensing model. The company out-licensed three metabolic candidates — including the injectable GLP-1/GIP dual agonist HRS-9531 and the oral GLP-1 candidate HRS-7535 — to Hercules CM NewCo, a newly established entity backed by $400 million from Bain Capital Life Sciences, RTW Investments, Atlas Venture, and Lyra Capital.¹⁷ Hengrui received $110 million in upfront and near-term payments, approximately a 20% equity stake in the new company, and up to $5.7 billion in potential contingent milestone payments.¹⁷ In October 2024, the entity publicly launched as Kailera Therapeutics, led by former Gilead chief executive John Milligan as chairman and former Cerevel and Translate Bio chief executive Ron Renaud as CEO.¹⁸

The "NewCo" model addresses limitations inherent in conventional out-licensing agreements. In standard licensing deals, originators transfer asset rights for upfront cash and royalties, capping long-term upside while relinquishing control over clinical development timelines. Under the NewCo framework, Western venture capital funds an independent entity managed by experienced Western biotech executives tasked with navigating FDA regulatory pathways. By retaining equity, the originator participates directly in value creation driven by global clinical execution and capital market access.

The metabolic portfolio subsequently generated clinical and market benchmarks. In China, Hengrui's Phase 3 trial of HRS-9531 in 567 adults with obesity demonstrated a mean weight loss of up to 17.7% at 48 weeks under the primary analysis and 19.2% in a pre-specified supplementary analysis, compared with 1.4% for placebo, with up to 88% of treated participants achieving at least 5% weight loss and 44.4% achieving at least 20%.¹⁹ While cross-trial comparisons remain subject to variations in trial design, baseline characteristics, and patient populations, the efficacy profile positioned the compound competitively within the broader obesity landscape. Kailera renamed the molecule ribupatide, completed a Nasdaq initial public offering under the ticker KLRA in April 2026 at $16 per share to raise $625 million in an upsized offering, and initiated a three-trial global Phase 3 program with primary data readouts anticipated in 2028.²⁰ The listing converted Hengrui's equity holding into a liquid, marked-to-market asset.

From molecules to a pipeline subscription

In March 2025, Merck & Co. licensed HRS-5346 — an oral small-molecule Lipoprotein(a) inhibitor then in Phase 2 clinical trials in China — acquiring rights outside Greater China for $200 million in upfront cash, up to $1.77 billion in potential milestone payments, and tiered royalties.²¹ Elevated Lipoprotein(a) affects approximately 20% of the global population as an independent cardiovascular risk factor lacking approved targeted therapies, making an oral candidate commercially significant alongside injectable therapies in development.

The alliance with GSK, announced on July 28, 2025, expanded the scope of Hengrui's global transactions. GSK acquired exclusive rights outside Greater China and Taiwan to HRS-9821, a dry-powder inhaler PDE3/4 inhibitor targeted at chronic obstructive pulmonary disease, complementing GSK's established respiratory portfolio.

Beyond the lead molecule, the transaction established a broader framework covering up to eleven additional research programs.²² Under the agreement, Hengrui advances candidates through Phase 1 clinical completion, after which GSK holds exclusive options for global development and commercialization. The structure involved $500 million in combined upfront payments, with potential success-based milestone payments approaching $12 billion.²²

The GSK framework shifted the deal model from individual asset transactions to a multi-year pipeline option structure, allowing a multinational partner to secure systematically generated early-stage candidates across specified therapeutic categories.

The partnership with Bristol Myers Squibb in May 2026 further extended this collaborative framework. In addition to a $600 million upfront payment and $175 million in scheduled anniversary payments in 2027 and 2028 (the second subject to contingencies), the thirteen-program transaction comprised four outgoing Hengrui oncology and hematology assets, four incoming BMS immunology assets for Greater China, and five joint discovery programs where Hengrui retained co-development and potential global commercialization options.¹

Hengrui designated the initiative internally as Project Beacon.²³ Under the transaction terms, Hengrui oversees early clinical development, BMS assumes worldwide commercialization rights outside mainland China, Hong Kong, and Macau, and tiered royalties revert to Hengrui.¹ The transaction was slated to close in the third quarter of 2026, subject to regulatory antitrust review in the United States.¹

The joint discovery mechanism reflected a deeper level of integration, moving beyond asset acquisitions toward collaborative research programs where both parties share early-stage target selection and molecular design.

Selling some geographies, keeping others

Complementing these major transactions, targeted regional agreements addressed secondary commercial markets. In September 2025, Hengrui licensed its HER2-directed antibody-drug conjugate trastuzumab rezetecan (SHR-A1811) to Glenmark Pharmaceuticals for selected emerging markets, securing $18 million in upfront cash and up to $1.093 billion in milestone payments, while explicitly retaining commercial rights across the United States, Canada, Europe, and Japan.²⁴ The structure permitted Hengrui to monetize territories where it lacked direct commercial infrastructure while retaining developed-market rights for major partnerships or internal development.

By the first quarter of 2026, Hengrui had completed twelve international business development transactions since 2023 across out-licensing, NewCo formations, and strategic alliances.²⁵ To support its expanding global operations and diversify capital sources, Hengrui completed a dual listing on the Hong Kong Stock Exchange on May 23, 2025, issuing 224.5 million shares at HK$44.05 to raise HK$9.89 billion (approximately $1.26 billion), with institutional cornerstone investors including GIC, Invesco, Boyu Capital, Hillhouse, and Oaktree Capital; the shares closed up 25% on their trading debut at HK$55.15.²⁶³ Following full exercise of the over-allotment option, total gross proceeds reached HK$11.4 billion.⁴ The transaction marked the largest healthcare initial public offering on the Hong Kong exchange in 2025.²⁶

The expansion in global licensing and equity partnerships has addressed Hengrui's immediate cost-of-capital constraints and domestic pricing pressures by accessing international markets. However, the model requires surrendering majority commercial upside in major Western markets to partners. Whether out-licensing early-stage assets serves as a permanent corporate model or a transitional strategy toward independent global commercialization remains the primary long-term question facing the company.

↑ Back to Top

VI. Segment Breakdown & Financial Engine (~25 min)

Behind the narrative, Hengrui entered 2025 operating three distinct product engines running at different speeds, with the divergence between them defining the core investment thesis.

Engine one: oncology, the mature core

The first and largest engine remains oncology. Innovative drug sales reached RMB 16.34 billion in 2025, a 26.1% increase that represented 58.34% of total drug sales revenue.⁴ Within that innovative portfolio, oncology products generated RMB 13.24 billion, growing 18.5%.⁴

This division encompasses established therapies like camrelizumab, apatinib, pyrotinib, and adebrelimab—a mature, reimbursed portfolio facing active domestic competition. Its growth rate reflects a predictable dynamic: expanding patient volume offset by recurring price reductions during national insurance reimbursement renewals.

Oncology has evolved from Hengrui's primary growth driver into a cash-generative commercial base. Management is gradually transitioning this portfolio toward next-generation platform chemistry, centered on antibody-drug conjugates (ADCs).

An antibody-drug conjugate functions as a targeted biological vehicle, tethering a monoclonal antibody that targets tumor-specific proteins to a cytotoxic payload potent enough that non-targeted systemic delivery would cause severe toxicity. Once the antibody attaches to the tumor cell and the cell internalizes the complex, the chemical linker releases the payload inside the target. The core engineering challenge lies in optimizing linker stability and drug-to-antibody ratios—delivering adequate therapeutic payload to the tumor while preventing premature release in bloodstream circulation. This reliance on synthetic chemistry and complex conjugation plays directly to the core technical discipline Hengrui has developed since 1991.

Hengrui's lead ADC asset, SHR-A1811, pairs trastuzumab with a novel topoisomerase-I inhibitor payload. Approved in China in May 2025 for previously treated HER2-mutated non-small cell lung cancer—making it the first domestically developed ADC approved for that indication—SHR-A1811 holds nine breakthrough therapy designations across lung, breast, gastric, colorectal, biliary, and gynecologic cancers, and received United States FDA orphan drug designation in August 2025 for gastric and gastroesophageal junction adenocarcinoma in combination therapies.²⁴

The global reference standard in this class is Daiichi Sankyo and AstraZeneca's Enhertu, which built a multi-billion-dollar franchise on the same target. Because Hengrui has not published direct head-to-head clinical trial data against Enhertu, claims regarding SHR-A1811's relative therapeutic profile remain hypotheses supported by single-arm and randomized Chinese clinical data rather than definitive comparative trials.

Engine two: the metabolic acceleration

The second engine—and the primary driver altering Hengrui's top-line growth trajectory across 2025 and 2026—is non-oncology innovation. Revenue from non-oncology innovative products rose 73.4% in 2025 to RMB 3.10 billion.⁴

That momentum accelerated in the first quarter of 2026. Non-oncology innovative sales reached RMB 1.213 billion, up 92.1% year over year, while oncology innovative revenue rose 11.6% to RMB 3.313 billion.²⁵ Driven by this shift, total first-quarter revenue grew 13.0% to RMB 8.141 billion, net profit climbed 21.8% to RMB 2.282 billion, and innovative therapies reached a company-milestone 61.69% of overall drug sales revenue.²⁵

This expansion centers on metabolic and autoimmune therapeutic areas, led by Hengrui's GLP-1/GIP receptor agonist portfolio, selective JAK inhibitors, and broader chronic disease candidates. The strategic significance lies in the market dynamics: whereas domestic oncology represents a heavily contested, hospital-tendered sector under tight pricing controls, metabolic care offers a broad patient base numbered in the hundreds of millions operating under a distinct commercial structure.

While rapid growth from a modest baseline does not automatically confirm long-term franchise durability, these operational metrics demonstrate that Hengrui's commercial infrastructure can execute product launches beyond its historical concentration in oncology.

Engine three: the legacy remainder

The third engine comprises legacy products: mature generics, medical imaging contrast agents such as iohexol and iodixanol, and surgical anesthesia formulations. Because Hengrui does not disclose disaggregated revenue figures for these individual product lines in its financial reports, exact segment breakdowns are unavailable. However, the overarching trend remains clear: this declining segment—representing roughly 42% of 2025 drug sales by calculation—has largely stabilized following initial volume-based procurement impacts into a predictable, low-margin, volume-guaranteed revenue base.⁴ The strategic utility of this legacy portfolio extends beyond operating margin: it continues to absorb fixed manufacturing overhead and maintains Hengrui's commercial footprint across national hospital procurement networks.

The fourth line: licensing income, and how to read it

Beyond product sales, a fourth contributor—licensing income—has become an increasingly significant driver of financial results. Licensing revenue rose 25.6% in 2025 to RMB 3.39 billion.⁴ In the first quarter of 2026, the company recorded RMB 787 million in out-licensing income, primarily derived from its partnership with GSK.²⁵

Evaluating this revenue stream requires an important accounting distinction. Upfront and milestone payments incur negligible direct cost of goods, flowing to net income at near-total profit margins—explaining why Hengrui's net profit growth has outpaced top-line expansion. However, these payments are periodic, transaction-dependent, and non-recurring.

Consequently, a meaningful portion of Hengrui's earnings expansion stems from corporate business development rather than recurring pharmaceutical consumption. While converting proprietary discovery into capital aligns with management's strategic shift, rigorous financial analysis requires distinguishing non-recurring licensing fees from baseline product revenues—a breakdown Hengrui's public disclosures provide only at an aggregate level.

R&D intensity and an accounting judgment

Despite operational transitions, Hengrui has sustained its research investment. R&D expenditure reached RMB 8.72 billion in 2025, accounting for 27.6% of total revenue, with RMB 6.96 billion expensed directly against earnings.⁴ In the first quarter of 2026, R&D intensity remained steady at 27.3% of revenue.²⁵

The treatment of non-expensed research expenses represents a key accounting parameter for ongoing monitoring. Approximately 20% of 2025 R&D expenditure was capitalized onto the balance sheet as an asset to be amortized over time rather than deducted immediately from operating income. While standard under Chinese Accounting Standards once clinical programs reach defined development thresholds, capitalization raises reported net income relative to an all-expensed accounting approach.

While current capitalization rates show no evidence of aggressive accounting, significant increases in capitalized R&D in future reporting periods—particularly during periods of earnings pressure—would warrant analytical scrutiny.

Hengrui's balance sheet remains exceptionally liquid. The company maintains negligible net debt alongside substantial liquidity, supported by its May 2025 Hong Kong listing proceeds and approximately $1 billion in licensing upfront payments received or contracted since 2023. Net interest income exceeded interest expense by more than fiftyfold in 2025. Supported by operating cash flows and partner capital, Hengrui finances a pipeline of roughly 100 clinical-stage programs internally without relying on debt-funded acquisition strategies to generate growth.

↑ Back to Top

VII. Management, Governance & Capital Allocation (~25 min)

In Chinese financial media, a photograph frequently circulates showing Sun Piaoyang at a shareholder meeting, sleeves rolled, answering technical questions about synthesis routes with the precision of an active research chemist. Now in his late sixties, Sun has directed the enterprise — save for a twenty-month sabbatical — since 1990. Understanding his capital allocation philosophy is essential to evaluating Hengrui's corporate trajectory.

What he spent money on

The defining characteristic of Sun's leadership is a focus on chemical synthesis rather than financial engineering. His strategic commitments have consistently prioritized research infrastructure: acquiring the ifosfamide patent in 1991, establishing the Shanghai research center in 2000, and maintaining R&D investment at roughly a quarter of revenue through the severe industry downturn of 2021 and 2022.

During those two years, when corporate revenue contracted by double digits and conventional executive strategy dictated cutting research to preserve operating margins, Hengrui expanded its research commitment. R&D spending rose from RMB 3.9 billion in 2019 to RMB 5.9 billion in 2021, remaining above RMB 4.9 billion throughout the earnings trough. That persistent capital commitment represents the defining operational metric of management's long-term orientation.

What he refused to buy

Equally significant is what management chose not to pursue. Hengrui avoided large cross-border acquisitions during an era when Chinese conglomerates paid premium valuations for Western biotech assets and Hengrui possessed both balance sheet liquidity and regulatory support to execute international transactions.

Instead, the company pursued the inverse model: out-licensing early-stage pipeline assets to Western partners and allowing international licensees to fund resource-intensive late-stage trials. The underlying financial rationale was clear: acquiring Western biotech targets required paying for clinical-stage risk at developed-market valuations using cash flows generated at Chinese pharmaceutical margins. Refusing to pursue high-priced cross-border acquisitions represented a distinct form of capital discipline that ultimately insulated the company from severe asset write-downs.

The corporate ownership structure aligns executive incentives with long-term capital allocation. Jiangsu Hengrui Pharmaceutical Group, controlled by Sun and Zhong Huijuan, is the controlling shareholder of the listed company, holding roughly a fifth to a quarter depending on look-through treatment.⁸ Furthermore, employee share ownership plans link staff compensation directly to novel drug approvals and out-licensing milestones, aligning incentive structures with pipeline productivity, though detailed vesting mechanics are disclosed with limited granular visibility.

The credibility stress test

A neutral assessment of Hengrui's corporate governance reveals several structural vulnerabilities.

The 2020 executive succession and Sun's subsequent return in August 2021 highlighted a clear governance challenge. Reversing a twenty-month leadership transition under market pressure demonstrated that executive succession had been improperly timed or inadequately structured. Consequently, the firm confronted its most severe commercial contraction without a settled leadership team, while four vice general managers and the oncology chief medical officer departed.¹³

While Sun's return stabilized operations, it reset the succession clock. As of August 2026, the company has not publicly designated a successor with an operational mandate. For an organization whose corporate identity and research culture have been shaped by one individual over thirty-five years, leadership continuity remains an unaddressed risk.

A second issue involves disclosure practices during the commercial downturn. Investors reviewing 2021 corporate filings received limited product-level quantification of volume-based procurement exposure until margin compression was already reflected in financial results. Because national tender calendars and product lists were publicly available, the decision to withhold detailed risk disclosures reduced market transparency during a critical operational pivot.

Third, management has acknowledged the primary bottleneck constraining its international expansion. In a Reuters analysis published in July 2026 examining global operational staffing among Chinese drugmakers, Hengrui's chairman noted that the industry faces a structural shortage of executives with global clinical development, international regulatory, and cross-cultural management expertise, acknowledging that recruiting such talent has become costly due to global scarcity.²⁷ The reporting highlighted that China-headquartered sponsors conducted 88% of their clinical trials exclusively within China in 2025, compared to 5% for U.S. sponsors — a structural disparity relative to the multi-regional trial requirements demanded by Western regulatory authorities.²⁷

This acknowledgment underscores the operational constraints surrounding the current out-licensing framework. Hengrui's licensing model succeeds partly because the firm currently lacks the specialized infrastructure required to run multi-center global Phase 3 trials independently. Out-licensing generates non-dilutive capital, but it also reflects an operational limitation: the company cannot yet navigate late-stage global commercialization unassisted.

Capturing full commercial value in developed markets — rather than relying on single-digit or low-double-digit royalties — requires regulatory affairs, clinical operations, and commercial networks that Hengrui does not currently possess.

Management has stated it will strengthen internal training and expand global recruitment.²⁷ However, the company has not disclosed specific timelines, headcount targets, or capital allocations to support that objective. Investors must view the strategic transition from an early-stage licensor to an independent global pharmaceutical operator as an unverified execution path until concrete operational milestones are established.

What emerges is a management team with a strong record in long-horizon research investment and disciplined capital deployment, contrasted with ongoing challenges in executive succession, corporate disclosure, and international operational capabilities. These structural factors directly shape Hengrui's long-term competitive positioning.

↑ Back to Top

VIII. Strategic Frameworks: Hamilton Helmer's 7 Powers & Porter's 5 Forces (~30 min)

Evaluating Hengrui through established strategic frameworks tests whether its market position reflects a durable competitive advantage or a temporary operational adaptation.

Hamilton Helmer's 7 Powers

Scale economies — real, but geographically bounded. Hengrui operates one of the largest clinical development organizations in China, with more than 100 proprietary innovative products under development and over 400 clinical trials underway as of its 2025 financial results, including 28 candidates entering Phase 3, 61 advancing to Phase 2, and 28 new molecular entities entering Phase 1 during that year.⁴

Conducting clinical trials at this volume generates meaningful fixed-cost leverage across investigator networks, hospital relationships, regulatory filings, and statistical infrastructure that smaller domestic biotechs cannot easily replicate. Management has guided to 53 innovative product or indication approvals across the 2026–2028 period.⁴

However, this scale advantage remains geographically constrained. While formidable within mainland China, management has acknowledged that the organization lacks the scale and international infrastructure required to execute multi-regional global clinical trials independently.²⁷ Consequently, Hengrui possesses a domestic scale power that it monetizes through foreign partners rather than a global scale power.

Process power — a compelling claim with rising peer competition. The core thesis is that thirty-five years of accumulated expertise in synthetic chemistry, now expanded into antibody-drug conjugate linker-payload design, enables Hengrui to identify candidate molecules faster and more reliably than domestic competitors.

External validation for this claim is substantial: major international pharmaceutical partners have committed significant capital to access the output rate of Hengrui's discovery engine, as reflected in GSK's option on up to eleven future research programs and Bristol Myers Squibb's commitment to five jointly discovered assets.²²¹ Multinational corporations paying upfront capital to secure access to an R&D engine provides clear commercial verification of process capabilities.

However, process power in synthetic chemistry can be replicated by rival Chinese firms operating under similar domestic cost structures. Cross-border out-licensing transactions originating from Greater China reached roughly $136 billion to $138 billion in total announced deal value in 2025, up from a few hundred million dollars a decade earlier.²⁷²⁸ Hengrui remains the largest participant in this broader industrial trend rather than its sole proprietor.

Counter-positioning — a structural cost asymmetry. Counter-positioning occurs when a challenger adopts a business model that incumbents cannot copy without disrupting their existing operations.

Multinational pharmaceutical companies cannot replicate Hengrui's early-stage development economics without restructuring their internal R&D organizations, altering Western research salary scales, or sacrificing established legacy operations. Conversely, Hengrui lacks a major Western commercial infrastructure, allowing it to license global rights to international partners without cannibalizing existing regional revenue.

This operational asymmetry allows each party to leverage capabilities the other structurally lacks. However, this strategic alignment remains exposed to geopolitical and trade policy friction, an external vulnerability outside the scope of traditional business model frameworks.

Branding, network economies, cornered resources, and switching costs — largely absent. While Hengrui commands strong physician familiarity across Chinese hospitals, that presence confers minimal pricing power within centralized procurement tenders. Network effects are non-existent in drug discovery. The company holds no exclusive cornered resources, as core targets remain broadly pursued across the industry and early assets like apatinib originated through external licensing. Furthermore, hospital switching costs between therapeutic equivalents like reimbursed PD-1 inhibitors are virtually non-existent. Analytical rigor requires recognizing that four of the seven structural powers do not apply to Hengrui's business.

Porter's Five Forces

Buyer power — extreme and structural. The National Healthcare Security Administration operates as a monopsony buyer with statutory authority over drug pricing and reimbursement volume across the national health insurance system. As demonstrated during the 2020–2022 revenue contraction, the agency uses its purchasing power to compress margins on off-patent generics and novel therapies alike. Although Hengrui's relative exposure is moderating as non-oncology innovation and international licensing revenue expand, buyer power remains the single most dominant and structurally unfavorable force shaping its domestic commercial business.

Rivalry — intense and escalating across markets. Within Greater China, Hengrui competes against domestic biotechs including BeiGene, Innovent, 石药集团 CSPC Pharmaceutical Group, 康方生物 Akeso, and 荣昌生物 RemeGen, several of which hold technical leads in specific therapeutic modalities. Internationally, Hengrui's out-licensed molecules face competition from global majors such as AstraZeneca, Merck, Eli Lilly, Novo Nordisk, and Daiichi Sankyo. In metabolic care, for example, primary data readouts from Kailera's global Phase 3 trials for ribupatide are anticipated in 2028, entering a commercial market where Eli Lilly and Novo Nordisk will have established multi-year leads in manufacturing capacity, payer coverage, and label expansions.²⁰ Entering a mature therapeutic category behind established incumbents presents severe commercial friction regardless of initial clinical efficacy.

Threat of new entrants — moderate domestically, rising in licensing. Building a vertically integrated domestic pharmaceutical enterprise with nationwide hospital distribution represents a formidable barrier to entry. Conversely, establishing an early-stage discovery biotech designed to out-license candidate molecules to Western partners requires far less capital, supported by returning scientific talent, venture funding, and expanded contract research infrastructure. Consequently, the out-licensing channel—the fastest-growing component of Hengrui's corporate valuation—represents its least defended business segment against new domestic entrants.

Substitutes — moderate over the long term. Advanced therapeutic modalities such as cell and gene therapies, mRNA platforms, and radiopharmaceutical conjugates may eventually displace established small-molecule and monoclonal antibody classes, though not within the commercial lifecycle of Hengrui's immediate pipeline. The primary near-term substitution risk stems from within-class product iterations, where a competing antibody-drug conjugate or multi-receptor agonist demonstrates superior clinical efficacy or safety, displacing earlier therapies.

Supplier power — low and structurally favorable. Hengrui's historical origin as an active pharmaceutical ingredient manufacturer provides vertical integration rare among biopharmaceutical firms. Internal ingredient manufacturing insulates the company from supplier pricing pressure and protects its supply chain against international geopolitical trade disruptions.

In summary, Hengrui commands two distinct strategic powers (process power and counter-positioning), one bounded domestic advantage (scale economies), one favorable structural factor (low supplier power), and one permanently adverse force (buyer power). The resulting competitive profile is robust yet conditional—dependent above all on domestic reimbursement policy and international trade stability.

↑ Back to Top

IX. Bear vs. Bull Case & Investment Spine (~25 min)

The spine of this investment is a single question, and it should be stated without hedging: can Hengrui convert a domestically constrained, price-controlled drug business into a global platform whose economics are set by international markets rather than by Chinese policy — and can it do so while retaining enough of the value it creates?

Everything else is detail.

The bull case

The bull case rests on three legs, each backed by empirical evidence.

First, the monetization engine is real and demonstrably repeatable. Twelve overseas transactions since 2023—including five with major multinationals in 2025 alone—span conventional licensing, NewCo equity, and full strategic alliances.²⁵⁴ The cash is not theoretical: Hengrui recognized RMB 3.39 billion of licensing revenue in 2025 and RMB 787 million in the first quarter of 2026 alone.⁴²⁵ More significantly, the structure of the deals has escalated: from a single asset with Merck KGaA in 2023, to a platform option package with GSK in 2025, to a bidirectional alliance featuring joint discovery with Bristol Myers Squibb in 2026.¹⁶²²¹ Counterparties who were buying single molecules three years ago are now contracting for discovery capability. That escalation is the strongest evidence that Hengrui's research engine is genuinely differentiated.

Second, the revenue mix shift is proceeding on schedule. Innovative therapies reached 58.34% of drug sales in 2025 and 61.69% in the first quarter of 2026.⁴²⁵ Non-oncology innovative revenue nearly doubled year over year in Q1 2026.²⁵ The mechanical implication is direct: as the generic base shrinks, additional volume-based procurement rounds exert diminishing influence on overall financial performance. A business where tender pricing controlled two-thirds of revenue in 2020 now sees that exposure reduced to roughly one-third and falling.

Third, the pipeline assets have generated clinical data that international partners are willing to fund. Domestic Phase 3 obesity results positioned HRS-9531 competitively among incretin therapies.¹⁹ Lead ADC asset SHR-A1811 holds regulatory approval in China alongside nine breakthrough therapy designations.²⁴ The Lp(a) and PARP1 programs target validated biological mechanisms with established commercial precedents.²¹¹⁶ Furthermore, Hengrui retains Greater China commercial rights across these programs—meaning that if global partners succeed in late-stage development, Hengrui collects royalties alongside a domestically commercialized franchise validated by international clinical data.

The bear case

The bear case does not merely counter the bullish narrative; it targets structural vulnerabilities in the business model.

Geopolitics is the dominant risk, and it remains outside management's control. In 2026, the U.S. administration circulated a draft executive order that would impose severe restrictions on American pharmaceutical companies licensing candidate drugs from Chinese biotechs, including mandatory transaction reviews by the Committee on Foreign Investment in the United States.²⁸

In Congress, lawmakers introduced the Biotech Investment National Security Act on June 2, 2026, followed by a bipartisan Senate version on August 6, 2026, aimed at extending outbound investment screening to pharmaceutical and biologics transactions with Chinese firms.²⁹ Major multinational pharmaceutical companies, including Pfizer and AstraZeneca, have actively opposed the proposed executive restrictions as primary buyers in this licensing market.²⁸

However, investors cannot underwrite a long-term business model on the assumption that industry lobbying will permanently override national security policy. If mandatory CFIUS review is applied to China-origin licensing, transaction timelines will lengthen, deal flow will slow, and asset valuations will decline as the prospective buyer pool narrows and execution risk increases. Hengrui's strategic pivot relies on a cross-border licensing channel that a single U.S. executive action could substantially impair. Additionally, the transaction with Bristol Myers Squibb remained subject to U.S. antitrust clearance at announcement.¹

The second risk is that Hengrui may have monetized its pipeline assets cheaply. A rigorous evaluation requires examining the underlying deal terms. The BMS alliance's headline $15.2 billion figure represents a cumulative "biobucks" projection—the aggregate sum of all potential milestones across thirteen programs assuming complete clinical and commercial success, an outcome rare in early-stage drug development.¹

Contractually committed terms specify $600 million in upfront cash and $175 million in scheduled near-term payments.¹ Across thirteen programs, including five joint discovery efforts, that translates to roughly $60 million in guaranteed capital per program—less than the cost of funding a single global Phase 3 clinical trial. Similar economics apply to GSK's $500 million committed capital against a $12 billion headline figure covering twelve programs.²²

If two or three of these molecules become billion-dollar global therapies, Hengrui will receive modest royalties on the value it discovered, while the majority of commercial upside accrues to its international partners. While this arrangement reflects Hengrui's current inability to execute global clinical trials independently, headline deal figures systematically overstate expected shareholder returns.

Third, clinical execution risk resides with counterparties. Once an asset is out-licensed, trial design, execution timelines, and portfolio prioritization are governed in Princeton or London rather than Lianyungang. Global pharmaceutical majors routinely deprioritize licensed candidates when internal strategies or portfolio priorities shift. Consequently, Hengrui's contingent milestone revenue depends on decisions it cannot direct, made by organizations managing broad competitive pipelines.

Fourth, domestic pricing pressure remains an ongoing constraint. Every new indication approved for camrelizumab and every novel product entering national coverage must undergo annual NRDL price negotiations—the same mechanism that reduced domestic PD-1 prices by 85% in 2020.¹⁴ Top-line expansion in innovative drugs is achieved partly by accepting lower unit prices in exchange for volume reimbursement. The contrast between 18.5% oncology growth and 73.4% non-oncology growth in 2025 illustrates where pricing pressure remains concentrated.⁴

Fifth, and most fundamental: Hengrui's corporate strategy depends on operational capabilities its leadership acknowledges it lacks. The global talent deficit is a primary operational bottleneck.²⁷ It represents the binding constraint preventing the company from graduating from an early-stage licensor into an independent global commercial operator.

An activist's angle

A skeptical institutional investor would focus on three specific corporate governance issues.

First, financial disclosure. Hengrui reports aggregate figures for innovative versus generic sales and a single line item for licensing income, but omits product-level revenue and segment profitability for contrast media, surgical anesthesia, and mature generics—preventing external investors from independently modeling the baseline cash-generative business or isolating recurring commercial sales from periodic licensing receipts.⁴

Second, R&D accounting policies. Approximately 20% of 2025 research spending was capitalized as balance-sheet assets rather than expensed directly against operating income.⁴

Third, executive succession and key-person risk. Founder Sun Piaoyang remains at the helm in his late sixties following an aborted leadership transition, with no publicly designated successor and a corporate research culture built largely around his personal direction.

While none of these issues represent regulatory failures, each justifies an analytical discount on corporate valuation.

The three KPIs that matter

Evaluating Hengrui's long-term transformation requires tracking three primary operational metrics:

1. Innovative drug revenue as a percentage of total drug sales. This metric provides the clearest indicator of structural business model transition. Innovative therapies accounted for 58.34% of sales in 2025 and 61.69% in the first quarter of 2026.⁴²⁵ Management has targeted an innovative share above 70%. Stagnation in this ratio would indicate that novel products are encountering NRDL pricing ceilings or that generic erosion has plateaued—either representing an early signal of operational friction.

2. Cash licensing proceeds received, distinct from announced milestone totals. Evaluation must focus on actual upfront and milestone cash collected, reported in financial statements as licensing revenue.⁴ The gap between announced biobucks figures and realized cash receipts determines whether the out-licensing model delivers tangible financial returns over multi-year periods.

3. Ex-China Phase 3 clinical readouts on partner-led programs. Primary global Phase 3 data for ribupatide are expected in 2028.²⁰ Programs optioned by GSK and BMS operate on distinct development schedules. Until a Hengrui-originated molecule achieves regulatory approval in Western markets following global clinical trials, the fundamental thesis—that domestic discovery capabilities translate into international commercial value—remains unproven. A successful Western approval would re-rate the valuation profile of the company and the broader Chinese biopharmaceutical sector; a high-profile clinical failure would reinforce market skepticism.

↑ Back to Top

X. Epilogue & Lessons (~15 min)

In 1991, a factory director in Lianyungang allocated his plant's entire annual profit to acquire an oncology patent from a Beijing research institute because the legacy commodity business could not generate adequate returns. Thirty-three years later, in 2024, the company that grew out of that factory transferred three obesity molecules to a Boston-backed venture for $110 million up front and a 20% equity stake, driven by a similar structural constraint in its domestic market.⁷¹⁷ Across three decades, the core operational logic remained consistent: when a legacy commercial model no longer funds research, alter the business model rather than curtailing research.

That strategy highlights the first broader takeaway from Hengrui's evolution. The company funded a multi-decade transition into proprietary research using cash flows from mature commodity active ingredients and generic formulations. Rather than defending declining product lines, management treated mature assets as capital sources for new development. Even as volume-based procurement compressed legacy generic margins, Hengrui sustained and increased its research budget through its steepest revenue contraction, prioritizing long-term pipeline development over short-term earnings defense.

The second insight involves the structure of China's biopharmaceutical sector in 2026. The industry is neither a simple lower-tier generic market nor a fully realized global equal to Western pharmaceutical majors. Substantial upfront licensing payments from international leaders—including Merck KGaA, Merck & Co., GSK, and Bristol Myers Squibb—reflect genuine commercial valuation of early-stage discovery rather than imitation.¹⁶²¹²²¹ At the same time, domestic firms have yet to establish independent global commercialization infrastructure.

Instead, the global biopharmaceutical value chain has bifurcated. Chinese developers specialize in early-stage discovery, target selection, synthetic chemistry, and initial clinical proof-of-concept. Conversely, late-stage execution—spanning multi-regional Phase 3 trials, international regulatory clearance, pricing negotiations, and commercial distribution—remains centered in Western markets. Hengrui's chairman publicly acknowledged in July 2026 that domestic firms still lack sufficient senior talent with global clinical and regulatory expertise.²⁷ The surge in cross-border out-licensing deal volume, expanding from a few hundred million dollars a decade ago to over $100 billion in total announced value in 2025, reflects the market pricing this specialized division of labor.²⁷

Whether this division of labor persists depends primarily on policy and organizational execution. Tightened trade or security screening by Western regulators could restrict cross-border licensing channels, narrowing early-stage arbitrage opportunities for Chinese developers. Alternatively, if domestic firms successfully build internal global clinical operations, they can retain assets through late-stage development and capture broader commercial returns. If the status quo endures, Chinese originators will remain specialized discovery engines, generating steady licensing income while relinquishing primary commercial upside to multinational partners equipped with global scale.

For founder Sun Piaoyang, now in his late sixties, resolving this transition represents his final strategic focus. Having returned to operational leadership in 2021 after a short-lived retirement, Sun faces the challenge of building the very international operational capabilities he acknowledged the company currently lacks.²⁷⁷

Hengrui's scale has transformed significantly since its origins as a regional state enterprise. Reporting RMB 31.6 billion in 2025 revenue, maintaining over 100 clinical-stage innovative programs, allocating more than a quarter of sales to research, holding dual exchange listings in Shanghai and Hong Kong, and partnering with major international pharmaceutical companies like Bristol Myers Squibb, the firm commands a major industry footprint.⁴¹ Yet its fundamental operational reality remains balanced between domestic single-buyer pricing constraints and reliance on international partners for global trial execution.

Hengrui's equity valuation reflects this balanced outlook. While the stock has recovered notably from its 2022 lows, it trades at approximately half its early 2021 peak.⁵⁶ Financial markets have priced neither a complete global commercial breakthrough nor a permanent domestic slowdown. Instead, valuations reflect ongoing execution risk, with key empirical evidence awaiting primary Phase 3 clinical trial readouts from foreign partners expected in 2028 and beyond.

Ultimately, Hengrui serves as a central case study in whether early-stage drug discovery and global late-stage clinical development can be decoupled across continents, corporate structures, and cost models while generating sustainable capital returns. As multi-regional clinical trials progress and out-licensed candidate molecules advance through international regulatory channels, the coming years will determine whether this cross-border R&D arbitrage model represents a permanent structural realignment of the global biopharmaceutical industry.

Jiangsu Hengrui Medicine Co., Ltd.

Table of Contents

Jiangsu Hengrui Medicine: The Story of China's Pharma Goliath

I. Introduction & Episode Roadmap (~15 min)

The company, in numbers

The roadmap

II. Lianyungang Roots & Sun Piaoyang's Early Bet (1970s–2000) (~25 min)

Escaping the commodity

Listing, and the geography of talent

The buyout, and what it means for governance

III. The Innovative Transformation: Dominating Domestic Oncology (2001–2019) (~35 min)

Apatinib, and a myth worth correcting

"722": the day the competition disappeared

PD-1: the best commercial setup in China, briefly

The power couple, and a governance footnote

IV. The VBP & NRDL Shock: The Dark Days of 2020–2022 (~30 min)

How volume-based procurement actually works

The PD-1 price war

The numbers, and what management did not say

The founder comes back

V. The Global BD & "NewCo" Revolution (2023–2026) (~40 min)

Proof point one: Merck KGaA

Inventing the NewCo

From molecules to a pipeline subscription

Selling some geographies, keeping others

VI. Segment Breakdown & Financial Engine (~25 min)

Engine one: oncology, the mature core

Engine two: the metabolic acceleration

Engine three: the legacy remainder

The fourth line: licensing income, and how to read it

R&D intensity and an accounting judgment

VII. Management, Governance & Capital Allocation (~25 min)

What he spent money on

What he refused to buy

The credibility stress test

VIII. Strategic Frameworks: Hamilton Helmer's 7 Powers & Porter's 5 Forces (~30 min)

Hamilton Helmer's 7 Powers

Porter's Five Forces

IX. Bear vs. Bull Case & Investment Spine (~25 min)

The bull case

The bear case

An activist's angle

The three KPIs that matter

X. Epilogue & Lessons (~15 min)

References